InspireMD Inc. (NSPR)

In our clinical practice, the efficacy of the CGuard Prime carotid stent system remains strong for stroke prevention, but the voluntary U.S. recall of the 135 cm delivery system in May has caused significant workflow adjustments. We are watching closely to see how quickly the delivery system issues are permanently resolved by regulatory bodies so domestic procedures can normalize without unexpected disruptions.

On our biotech desk, NSPR's recent Q2 2026 print was a stark reality check. While international sales managed a 21% year-over-year bump, the domestic blackout quarter and recall credits of $734k completely obliterated GAAP gross margins down to -43.7%. The market reaction has been brutal, sending the stock tumbling over 10% post-earnings as investors digest the true cost of the U.S. setback.

Watching the 50-day moving average and recent 10-Q filings, the inclusion of going concern and Nasdaq risk flags is alarming. Even with a 20% workforce reduction designed to align the cost structure, six-month operating expenses remain aggressively high with RandD at $9.06 million and sales/marketing at $10.40 million against a market capitalization of just $33.72 million.

As a healthcare analyst reviewing the sentiment data, the resignation of director Raymond W. Cohen effective July 1, 2026, adds another layer of boardroom transition turbulence right on the heels of withdrawn full-year guidance. Sentiment remains neutral-to-negative as market participants wait to see if international sales can shoulder the load during prolonged domestic headwinds.

From a clinical evaluation standpoint, the positive CGUARDIANS II data for CGuard Prime TCAR provides long-term technical validation of the platform. However, translating clinical success into commercial momentum in the U.S. is currently bottlenecked by the delivery system remediation process, making near-term adoption highly dependent on regulatory clearance timelines.